Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227110 · ClinicalTrials.gov registry record · Phase 4
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
A Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
NCT00227110 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 55 participants.
The verdict
NCT00227110, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
Study Summary
To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG Pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00227110
The ClinicalTrials.gov registry entry for NCT00227110 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00227110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00227110 about?
NCT00227110 is a clinical study titled "Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)". To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT00227110?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2002-10. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00227110?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00227110?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.